Alfacell Plans Subset Onconase NDA Despite Phase III Shortfall In Mesothelioma
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug works in chemo failures; filing by year’s end, CFO tells “The Pink Sheet” DAILY.
You may also be interested in...
Troubled Biotechs Roundup: Avigen, Jazz, Alfacell, Panacos
Unlike other troubled biotechs, Avigen is not cash-poor; however, it is not advancing its small pipeline and its largest investor has called foul.
Troubled Biotechs Roundup: Avigen, Jazz, Alfacell, Panacos
Unlike other troubled biotechs, Avigen is not cash-poor; however, it is not advancing its small pipeline and its largest investor has called foul.
Alfacell Finishes Six-Year Mesothelioma Study
Firm opens Phase IIIb database on would-be competitor to Lilly’s Alimta.